SEARCH

SEARCH BY CITATION

References

  • Alvarez-Larran, A., Cervantes, F., Bellosillo, B., Giralt, M., Julia, A., Hernandez-Boluda, J.C., Bosch, A., Hernandez-Nieto, L., Clapes, V., Burgaleta, C., Salvador, C., Arellano-Rodrigo, E., Colomer, D. & Besses, C. (2007) Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia, 21, 12181223.
  • Alvarez-Larran, A., Arellano-Rodrigo, E., Reverter, J.C., Domingo, A., Villamor, N., Colomer, D. & Cervantes, F. (2008) Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Annals of Hematology, 87, 269276.
  • Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V., Longo, G., Bosi, A. & Vannucchi, A.M. (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 19, 18471849.
  • Arellano-Rodrigo, E., Alvarez-Larran, A., Reverter, J.C., Villamor, N., Colomer, D. & Cervantes, F. (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica, 91, 169175.
  • Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Beck, M.R. Jr & Eckstein, E.C. (1980) Preliminary report on platelet concentration in capillary tube flows of whole blood. Biorheology, 17, 455464.
  • Berk, P.D., Goldberg, J.D., Donovan, P.B., Fruchtman, S.M., Berlin, N.I. & Wasserman, L.R. (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology, 23, 132143.
  • Boissinot, M., Lippert, E., Girodon, F., Dobo, I., Fouassier, M., Masliah, C., Praloran, V. & Hermouet, S. (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood, 108, 32233224.
  • Briere, J.B. (2006) Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Seminars in Thrombosis and Hemostasis, 32, 208218.
  • Camera, M., Frigerio, M., Toschi, V., Brambilla, M., Rossi, F., Cottell, D.C., Maderna, P., Parolari, A., Bonzi, R., De Vincenti, O. & Tremoli, E. (2003) Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 16901696.
  • Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. & Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 19451953.
  • Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A. & Barbui, T. (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood, 109, 23102313.
  • Cervantes, F., Alvarez-Larran, A., Arellano-Rodrigo, E., Granell, M., Domingo, A. & Montserrat, E. (2006) Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia, 20, 5560.
  • Chait, Y., Condat, B., Cazals-Hatem, D., Rufat, P., Atmani, S., Chaoui, D., Guilmin, F., Kiladjian, J.J., Plessier, A., Denninger, M.H., Casadevall, N., Valla, D. & Briere, J.B. (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. British Journal Haematology, 129, 553560.
  • Cheung, B., Radia, D., Pantelidis, P., Yadegarfar, G. & Harrison, C. (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. British Journal Haematology, 132, 244245.
  • Colaizzo, D., Amitrano, L., Iannaccone, L., Vergura, P., Cappucci, F., Grandone, E., Guardascione, M.A. & Margaglione, M. (2007a) Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. Journal of Medical Genetics, 44, 412416.
  • Colaizzo, D., Amitrano, L., Tiscia, G.L., Scenna, G., Grandone, E., Guardascione, M.A., Brancaccio, V. & Margaglione, M. (2007b) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. Journal of Thrombosis and Haemostasis, 5, 5561.
  • Colombi, M., Radaelli, F., Zocchi, L. & Maiolo, A.T. (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer, 67, 29262930.
  • Cortelazzo, S., Viero, P., Finazzi, G., D’Emilio, A., Rodeghiero, F. & Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Journal of Clinical Oncology, 8, 556562.
  • Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. & Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine, 332, 11321136.
  • De Stefano, V., Za, T., Rossi, E., Vannucchi, A.M., Ruggeri, M., Elli, E., Mico, C., Tieghi, A., Cacciola, R.R., Santoro, C., Gerli, G., Vianelli, N., Guglielmelli, P., Pieri, L., Scognamiglio, F., Rodeghiero, F., Pogliani, E.M., Finazzi, G., Gugliotta, L., Marchioli, R., Leone, G. & Barbui, T. (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 93, 372380.
  • Di Nisio, M., Barbui, T., Di Gennaro, L., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G., Marfisi, R., Porreca, E., Ruggeri, M., Rutjes, A.W., Tognoni, G., Vannucchi, A.M. & Marchioli, R. (2007) The haematocrit and platelet target in polycythemia vera. British Journal Haematology, 136, 249259.
  • Elliott, M.A. & Tefferi, A. (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British Journal Haematology, 128, 275290.
  • Falanga, A., Marchetti, M., Evangelista, V., Vignoli, A., Licini, M., Balicco, M., Manarini, S., Finazzi, G., Cerletti, C. & Barbui, T. (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 96, 42614266.
  • Falanga, A., Marchetti, M., Vignoli, A., Balducci, D. & Barbui, T. (2005) Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Experimental Hematology, 33, 523530.
  • Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., Russo, L., Guerini, V. & Barbui, T. (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Experimental Hematology, 35, 702711.
  • Finazzi, G. (2004) A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathologie-Biologie, 52, 285288.
  • Finazzi, G., Gregg, X.T., Barbui, T. & Prchal, J.T. (2006) Idiopathic erythrocytosis and other non-clonal polycythemias. Best Practice & Research. Clinical Haematology, 19, 471482.
  • Finazzi, G., Rambaldi, A., Guerini, V., Carobbo, A. & Barbui, T. (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica, 92, 135136.
  • Van Genderen, P.J. & Michiels, J.J. (1997) Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Seminars in Thrombosis and Hemostasis, 23, 357363.
  • Griesshammer, M. (2006) Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Seminars in Thrombosis and Hemostasis, 32, 372380.
  • Harrison, C.N. (2005) Platelets and thrombosis in myeloproliferative diseases. Hematology/The Education Program of the American Society of Hematology, 409415.
  • Harrison, C.N., Gale, R.E., Machin, S.J. & Linch, D.C. (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood, 93, 417424.
  • Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., Van Der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. & Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 3345.
  • Heller, P.G., Lev, P.R., Salim, J.P., Kornblihtt, L.I., Goette, N.P., Chazarreta, C.D., Glembotsky, A.C., Vassallu, P.S., Marta, R.F. & Molinas, F.C. (2006) JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. European Journal of Haematology, 77, 210216.
  • Hsiao, H.H., Yang, M.Y., Liu, Y.C., Lee, C.P., Yang, W.C., Liu, T.C., Chang, C.S. & Lin, S.F. (2007) The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Experimental Hematology, 35, 17041707.
  • James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 11441148.
  • Jensen, M.K., De Nully Brown, P., Lund, B.V., Nielsen, O.J. & Hasselbalch, H.C. (2000) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. British Journal Haematology, 110, 116124.
  • Jensen, M.K., De Nully Brown, P., Lund, B.V., Nielsen, O.J. & Hasselbalch, H.C. (2001) Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. European Journal of Haematology, 66, 143151.
  • Kiladjian, J.J., Cervantes, F., Leebeek, F.W., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatem, D., Plessier, A., Garcia-Pagan, J.C., Darwish Murad, S., Raffa, S., Janssen, H.L., Gardin, C., Cereja, S., Tonetti, C., Giraudier, S., Condat, B., Casadevall, N., Fenaux, P. & Valla, D.C. (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood, 111, 49224929.
  • Kittur, J., Knudson, R.A., Lasho, T.L., Finke, C.M., Gangat, N., Wolanskyj, A.P., Li, C.Y., Wu, W., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer, 109, 22792284.
  • Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005a) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 17791790.
  • Kralovics, R., Teo, S.S., Buser, A.S., Brutsche, M., Tiedt, R., Tichelli, A., Passamonti, F., Pietra, D., Cazzola, M. & Skoda, R.C. (2005b) Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 106, 33743376.
  • Kubota, Y., Tanaka, T., Ohnishi, H., Kitanaka, A., Okutani, Y., Taminato, T., Ishida, T. & Kamano, H. (2004) Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia, 18, 11271137.
  • Landolfi, R., Rocca, B. & Patrono, C. (1995) Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Critical Reviews in Oncology/Hematology, 20, 203222.
  • Landolfi, R., Marchioli, R. & Patrono, C. (1997) Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thrombosis and Haemostasis, 78, 617621.
  • Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G. & Marchioli, R. (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109, 24462452.
  • Lengfelder, E., Hochhaus, A., Kronawitter, U., Hoche, D., Queisser, W., Jahn-Eder, M., Burkhardt, R., Reiter, A., Ansari, H. & Hehlmann, R. (1998) Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. British Journal Haematology, 100, 1523.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D’Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G. & Barbui, T. (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology, 23, 22242232.
  • Maugeri, N., Giordano, G., Petrilli, M.P., Fraticelli, V., De Gaetano, G., Cerletti, C., Storti, S. & Donati, M.B. (2006) Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? Journal of Thrombosis and Haemostasis, 4, 25932598.
  • McMahon, C., Abu-Elmagd, K., Bontempo, F.A., Kant, J.A. & Swerdlow, S.H. (2007) JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. American Journal of Clinical Pathology, 127, 736743.
  • Michiels, J.J., Berneman, Z., Van Bockstaele, D., Van Der Planken, M., De Raeve, H. & Schroyens, W. (2006) Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Seminars in Thrombosis and Hemostasis, 32, 174207.
  • Michiels, J.J., Commandeur, S., Hoogenboom, G.J., Wegman, J.J., Scholten, L., Van Rijssel, R.H. & De Raeve, H. (2007) JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Annals of Hematology, 86, 793800.
  • Niittyvuopio, R., Juvonen, E., Kekomaki, R., Oksanen, K., Anttila, P. & Ruutu, T. (2004) The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complications in essential thrombocythaemia. European Journal of Haematology, 72, 245251.
  • Ohyashiki, K., Akahane, D., Gotoh, A., Ito, Y., Tauchi, T., Miyazawa, K., Kimura, Y. & Ohyashiki, J.H. (2007a) Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status. Leukemia, 21, 25442545.
  • Ohyashiki, K., Aota, Y., Akahane, D., Gotoh, A. & Ohyashiki, J.H. (2007b) JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia, 21, 10971099.
  • Ohyashiki, K., Ito, Y., Hori, K., Sato, K., Makino, T. & Ohyashiki, J.H. (2007c) Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan. Leukemia, 21, 15701571.
  • Pardanani, A., Lasho, T.L., Schwager, S., Finke, C., Hussein, K., Pruthi, R.K. & Tefferi, A. (2007) JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia, 21, 18281829.
  • Passamonti, F., Rumi, E., Pietra, D., Lazzarino, M. & Cazzola, M. (2007) JAK2 (V617F) mutation in healthy individuals. British Journal Haematology, 136, 678679.
  • Patel, R.K., Lea, N.C., Heneghan, M.A., Westwood, N.B., Milojkovic, D., Thanigaikumar, M., Yallop, D., Arya, R., Pagliuca, A., Gaken, J., Wendon, J., Heaton, N.D. & Mufti, G.J. (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology, 130, 20312038.
  • Pearson, T.C. (1997) Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Seminars in Thrombosis and Hemostasis, 23, 433439.
  • Pearson, T.C. & Wetherley-Mein, G. (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, 2, 12191222.
  • Primignani, M., Barosi, G., Bergamaschi, G., Gianelli, U., Fabris, F., Reati, R., Dell’Era, A., Bucciarelli, P. & Mannucci, P.M. (2006) Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 44, 15281534.
  • Ravandi-Kashani, F. & Schafer, A.I. (1997) Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives. Seminars in Thrombosis and Hemostasis, 23, 479488.
  • Regina, S., Herault, O., D’Alteroche, L., Binet, C. & Gruel, Y. (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis, 5, 859861.
  • Remacha, A.F., Estivill, C., Sarda, M.P., Mateo, J., Souto, J.C., Canals, C., Nomdedeu, J. & Fontcuberta, J. (2007) The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica, 92, 285286.
  • Rinder, H.M., Schuster, J.E., Rinder, C.S., Wang, C., Schweidler, H.J. & Smith, B.R. (1998) Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood, 91, 12881294.
  • Robertson, B., Urquhart, C., Ford, I., Townend, J., Watson, H.G., Vickers, M.A. & Greaves, M. (2007) Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7F status, clonality, and antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 5, 16791685.
  • Royer, Y., Staerk, J., Costuleanu, M., Courtoy, P.J. & Constantinescu, S.N. (2005) Janus kinases affect thrombopoietin receptor cell surface localization and stability. Journal of Biological Chemistry, 280, 2725127261.
  • Santos, M.T., Valles, J., Aznar, J., Marcus, A.J., Broekman, M.J. & Safier, L.B. (1997) Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation, 95, 6368.
  • Schafer, A.I. (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood, 64, 112.
  • Schafer, A.I. (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood, 107, 42144222.
  • Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459468.
  • Siddiqui, F.A., Desai, H., Amirkhosravi, A., Amaya, M. & Francis, J.L. (2002) The presence and release of tissue factor from human platelets. Platelets, 13, 247253.
  • Smalberg, J.H., Murad, S.D., Braakman, E., Valk, P.J., Janssen, H.L. & Leebeek, F.W. (2006) Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica, 91, 17121713.
  • Spivak, J.L. (2002) Polycythemia vera: myths, mechanisms, and management. Blood, 100, 42724290.
  • Stuart, M.J. & Nagel, R.L. (2004) Sickle-cell disease. Lancet, 364, 13431360.
  • Tefferi, A. & Hoagland, H.C. (1994) Issues in the diagnosis and management of essential thrombocythemia. Mayo Clinic Proceedings, 69, 651655.
  • Tefferi, A., Lasho, T.L., Schwager, S.M., Strand, J.S., Elliott, M., Mesa, R., Li, C.Y., Wadleigh, M., Lee, S.J. & Gilliland, D.G. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer, 106, 631635.
  • Ugo, V., Le Gal, G., Lecucq, L., Mottier, D. & Oger, E. (2007) Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. Journal of Thrombosis and Haemostasis, 6, 203205.
  • Valla, D., Casadevall, N., Lacombe, C., Varet, B., Goldwasser, E., Franco, D., Maillard, J.N., Pariente, E.A., Leporrier, M. & Rueff, B. (1985) Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Annals of Internal Medicine, 103, 329334.
  • Valles, J., Santos, M.T., Aznar, J., Martinez, M., Moscardo, A., Pinon, M., Broekman, M.J. & Marcus, A.J. (2002) Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood, 99, 39783984.
  • Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R.M., Finazzi, G., Guerini, V., Fabris, F., Randi, M.L., De Stefano, V., Caberlon, S., Tafuri, A., Ruggeri, M., Specchia, G., Liso, V., Rossi, E., Pogliani, E., Gugliotta, L., Bosi, A. & Barbui, T. (2007a) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110, 840846.
  • Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V., Bogani, C., Ferrini, P.R., Rambaldi, A., Guerini, V., Bosi, A. & Barbui, T. (2007b) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia, 21, 19521959.
  • Villmow, T., Kemkes-Matthes, B. & Matzdorff, A.C. (2002) Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thrombosis Research, 108, 139145.
  • Wautier, M.P., El Nemer, W., Gane, P., Rain, J.D., Cartron, J.P., Colin, Y., Le Van Kim, C. & Wautier, J.L. (2007) Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood, 110, 894901.
  • Wehmeier, A., Daum, I., Jamin, H. & Schneider, W. (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Annals of Hematology, 63, 101106.
  • Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., McClure, R.F., Wadleigh, M., Lee, S.J., Gilliland, D.G. & Tefferi, A. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal Haematology, 131, 208213.
  • Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R. & Tefferi, A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81, 159166.
  • Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q., Krantz, S.B., Fu, X. & Zhao, Z.J. (2007) JAK2(V617F): prevalence in a large Chinese hospital population. Blood, 109, 339342.
  • Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. & Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry, 280, 2278822792.